INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY
This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an induc...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HICKLIN, Daniel ISAACS, Randi SEIDEL-DUGAN, Cynthia SALMERON-GARCIA, Jose Andres BRODKIN, Heather WINSTON, William |
| description | This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4.
La présente invention concerne des procédés et des compositions pour le traitement du cancer à l'aide d'une polythérapie comprenant un promédicament IL-2 inductible en combinaison avec du pembrolizumab. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023023070A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023023070A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023023070A33</originalsourceid><addsrcrecordid>eNrjZDD09HMJdfZ08nFV8PTRNVJw9HNRCHDRNdQHEj6GCs7-vk6efo4hnv5-CiEerkGOAZE8DKxpiTnFqbxQmptB2c01xNlDN7UgPz61uCAxOTUvtSQ-3N_IwMgYhMwNHI2NiVMFAIZQJpc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY</title><source>esp@cenet</source><creator>HICKLIN, Daniel ; ISAACS, Randi ; SEIDEL-DUGAN, Cynthia ; SALMERON-GARCIA, Jose Andres ; BRODKIN, Heather ; WINSTON, William</creator><creatorcontrib>HICKLIN, Daniel ; ISAACS, Randi ; SEIDEL-DUGAN, Cynthia ; SALMERON-GARCIA, Jose Andres ; BRODKIN, Heather ; WINSTON, William</creatorcontrib><description>This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4.
La présente invention concerne des procédés et des compositions pour le traitement du cancer à l'aide d'une polythérapie comprenant un promédicament IL-2 inductible en combinaison avec du pembrolizumab.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230323&DB=EPODOC&CC=WO&NR=2023023070A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230323&DB=EPODOC&CC=WO&NR=2023023070A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HICKLIN, Daniel</creatorcontrib><creatorcontrib>ISAACS, Randi</creatorcontrib><creatorcontrib>SEIDEL-DUGAN, Cynthia</creatorcontrib><creatorcontrib>SALMERON-GARCIA, Jose Andres</creatorcontrib><creatorcontrib>BRODKIN, Heather</creatorcontrib><creatorcontrib>WINSTON, William</creatorcontrib><title>INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY</title><description>This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4.
La présente invention concerne des procédés et des compositions pour le traitement du cancer à l'aide d'une polythérapie comprenant un promédicament IL-2 inductible en combinaison avec du pembrolizumab.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDD09HMJdfZ08nFV8PTRNVJw9HNRCHDRNdQHEj6GCs7-vk6efo4hnv5-CiEerkGOAZE8DKxpiTnFqbxQmptB2c01xNlDN7UgPz61uCAxOTUvtSQ-3N_IwMgYhMwNHI2NiVMFAIZQJpc</recordid><startdate>20230323</startdate><enddate>20230323</enddate><creator>HICKLIN, Daniel</creator><creator>ISAACS, Randi</creator><creator>SEIDEL-DUGAN, Cynthia</creator><creator>SALMERON-GARCIA, Jose Andres</creator><creator>BRODKIN, Heather</creator><creator>WINSTON, William</creator><scope>EVB</scope></search><sort><creationdate>20230323</creationdate><title>INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY</title><author>HICKLIN, Daniel ; ISAACS, Randi ; SEIDEL-DUGAN, Cynthia ; SALMERON-GARCIA, Jose Andres ; BRODKIN, Heather ; WINSTON, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023023070A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HICKLIN, Daniel</creatorcontrib><creatorcontrib>ISAACS, Randi</creatorcontrib><creatorcontrib>SEIDEL-DUGAN, Cynthia</creatorcontrib><creatorcontrib>SALMERON-GARCIA, Jose Andres</creatorcontrib><creatorcontrib>BRODKIN, Heather</creatorcontrib><creatorcontrib>WINSTON, William</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HICKLIN, Daniel</au><au>ISAACS, Randi</au><au>SEIDEL-DUGAN, Cynthia</au><au>SALMERON-GARCIA, Jose Andres</au><au>BRODKIN, Heather</au><au>WINSTON, William</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY</title><date>2023-03-23</date><risdate>2023</risdate><abstract>This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4.
La présente invention concerne des procédés et des compositions pour le traitement du cancer à l'aide d'une polythérapie comprenant un promédicament IL-2 inductible en combinaison avec du pembrolizumab.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023023070A3 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T13%3A10%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HICKLIN,%20Daniel&rft.date=2023-03-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023023070A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |